Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

Lisa Lancaster, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Talmadge E King Jr, David J Lederer, Zhengning Lin, Steven D Nathan, Carlos A Pereira, Jeffrey J Swigris, Dominique Valeyre, Paul W Noble, Lisa Lancaster, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Talmadge E King Jr, David J Lederer, Zhengning Lin, Steven D Nathan, Carlos A Pereira, Jeffrey J Swigris, Dominique Valeyre, Paul W Noble

Abstract

Background: Pirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of safety data from five clinical trials evaluating pirfenidone in patients with IPF.

Methods: All patients treated with pirfenidone in the three multinational Phase 3 studies (CAPACITY (studies 004 and 006), ASCEND (study 016)) and two ongoing open-label studies (study 002 and study 012 (RECAP)) were included in the analysis. Safety outcomes were assessed during the period from the first dose until 28 days after the last dose of study drug.

Results: A total of 1299 patients were included in the analysis. The cumulative total exposure to pirfenidone was 3160 person exposure years (PEY). The median duration of exposure was 1.7 years (range 1 week to 9.9 years), and the mean (±SD) daily dose was 2053.8 (±484.9) mg. Gastrointestinal events (nausea (37.6%), diarrhoea (28.1%), dyspepsia (18.4%), vomiting (15.9%)) and rash (25.0%) were the most common adverse events; these were generally mild to moderate in severity and without significant clinical consequence. Elevations in alanine aminotransferase or aspartate aminotransferase greater than three times the upper limit of normal occurred in 40/1299 (3.1%) patients (adjusted incidence, 2.3 per 100 PEY). Elevations were generally transient and reversible with dose modification or discontinuation.

Conclusions: A comprehensive analysis of safety outcomes in a large and well-defined cohort of 1299 patients with IPF who were followed prospectively for up to 9.9 years demonstrated that long-term treatment with pirfenidone is safe and generally well tolerated.

Trial registration numbers: NCT00287716, NCT00287729, NCT00662038, NCT01366209.

Keywords: Interstitial Fibrosis.

Figures

Figure 1
Figure 1
Study profile.

References

    1. Raghu G, Collard HR, Egan JJ et al. . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788–824.
    1. Noble PW, Albera C, Bradford WZ et al. . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760–8.
    1. King TE Jr, Bradford WZ, Castro-Bernardini S et al. . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083–92.
    1. Taniguchi H, Ebina M, Kondoh Y et al. . Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821–9.
    1. Valeyre D, Albera C, Bradford WZ et al. . Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014;19:740–7.
    1. Azuma A, Nukiwa T, Tsuboi E et al. . Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040–7.
    1. Raghu G, Johnson WC, Lockhart D et al. . Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061–9.
    1. Rubino CM, Bhavnani SM, Ambrose PG et al. . Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009;22:279–85.
    1. Costabel U, Albera A, Bradford WZ et al. . Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:198–205.
    1. Esbriet [summary of product characteristics]. London, UK: InterMune UK Ltd, 2011.
    1. Esbriet (pirfenidone) capsules, for oral use [package insert]. Brisbane, CA: InterMune, Inc, 2014.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner